Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.57 |
| ▸ | USP2 | O75604 | 1/20 | 0.57 |
| ▸ | HPGD | P15428 | 3/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 4/20 | 0.55 |
| ▸ | RAB9A | P51151 | 4/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24898332 | 0.91 | LMNA (0.47) | LMNASMN1; SMN2USP2HPGDTP53 | |
| SCHEMBL10163734 | 0.86 | SMN1; SMN2 (0.60) | LMNASMN1; SMN2USP2HPGDTP53 | |
| SCHEMBL12409354 | 0.82 | SMN1; SMN2 (0.64) | LMNASMN1; SMN2USP2HPGDTP53 | |
| SCHEMBL12409226 | 0.82 | SMN1; SMN2 (0.64) | LMNASMN1; SMN2USP2HPGDTP53 | |
| SCHEMBL1101625 | 0.82 | SMN1; SMN2 (0.64) | LMNASMN1; SMN2USP2HPGDTP53 | |
| SCHEMBL14394851 | 0.82 | SMN1; SMN2 (0.54) | LMNASMN1; SMN2USP2HPGDTP53 | |
| SCHEMBL183586 | 0.80 | ALDH1A1 (0.47) | LMNASMN1; SMN2USP2HPGDTP53 | |
| SCHEMBL9507904 | 0.80 | LMNA (0.43) | LMNASMN1; SMN2USP2HPGDTP53 | |
| SCHEMBL6293470 | 0.79 | SMN1; SMN2 (0.64) | LMNASMN1; SMN2USP2HPGDTP53 | |
| SCHEMBL24575950 | 0.78 | HPGD (0.72) | LMNASMN1; SMN2USP2HPGDTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 584 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260040695-A1 | A METHOD TO GENERATE CONDUCTIVE POLYMER | NEWSOUTH INNOVATIONS PTY LTD (AU) | 2026-02-05 | — | — | US | claimed |
| WO-2025264622-A1 | MULTI-COMPONENT RESPONSIVE COPOLYMERS AND APPLICATIONS THEREOF | AESCULA TECH, INC. (US) | 2025-12-26 | — | — | WO | claimed |
| US-20250382404-A1 | MULTI-COMPONENT RESPONSIVE COPOLYMERS AND APPLICATIONS THEREOF | AESCULATECH INC (US) | 2025-12-18 | — | — | US | claimed |
| EP-4562077-A1 | A METHOD TO GENERATE CONDUCTIVE POLYMER | NewSouth Innovations Pty Limited (AU) | 2025-06-04 | — | — | EP | claimed |
| CN-115135307-B | Cell delivery vehicle | 株式会社ITO | 2024-11-22 | — | — | CN | claimed |
| WO-2024020649-A1 | A METHOD TO GENERATE CONDUCTIVE POLYMER | NEWSOUTH INNOVATIONS PTY LIMITED (AU) | 2024-02-01 | — | — | WO | claimed |
| US-11773300-B2 | Acrylic adhesive compositions and methods of making same | DOW GLOBAL TECHNOLOGIES LLC (US) | 2023-10-03 | — | — | US | claimed |
| US-20230055665-A1 | DELIVERY CARRIER INTO CELL | ITO, KABUSIKIKAISYA (JP) | 2023-02-23 | — | — | US | claimed |
| WO-2022261721-A1 | HEALABLE AND REPROCESSABLE COMPOSITIONS | DEAKIN UNIVERSITY (AU) | 2022-12-22 | — | — | WO | claimed |
| CN-115135307-A | Carrier for cell delivery | 株式会社ITO | 2022-09-30 | — | — | CN | claimed |
| EP-1873205-A1 | Thermo-responsive blends and uses thereof | CORNING INCORPORATED (US) | 2008-01-02 | — | — | EP | claimed |
| WO-2007144356-A1 | THERMO-RESPONSIVE BLENDS AND USES THEREOF | CORNING INCORPORATED (US) | 2007-12-21 | — | — | WO | claimed |
| US-20070211130-A1 | Fusible inkjet recording element and related methods of coating and printing | EASTMAN KODAK COMPANY | 2007-09-13 | — | — | US | claimed |
| WO-2006101548-A2 | POSTPARTUM CELLS DERIVED FROM UMBILICAL CORD TISSUE, AND METHODS OF MAKING, CULTURING, AND USING THE SAME | ETHICON, INC. (US) | 2006-09-28 | — | — | WO | claimed |
| WO-2006083394-A2 | POSTPARTUM CELLS DERIVED FROM PLACENTAL TISSUE, AND METHODS OF MAKING, CULTURING, AND USING THE SAME | ETHICON, INC. (US) | 2006-08-10 | — | — | WO | claimed |
| US-20060171930-A1 | Postpartum cells derived from umbilical cord tissue, and methods of making, culturing, and using the same | ADVANCED TECHNOLOGIES AND REGENERATIVE MEDICINE, LLC | 2006-08-03 | — | — | US | claimed |
| US-20060166361-A1 | Postpartum cells derived from placental tissue, and methods of making, culturing, and using the same | ETHICON, INC. | 2006-07-27 | — | — | US | claimed |
| US-20040191433-A1 | Ink-jet recording material | MITSUBISHI PAPER MILLS LIMITED (JP) | 2004-09-30 | — | — | US | claimed |
| US-5298554-A | Heating and solution polymerizing | BASF AKTIENGESELLSCHAFT (DE) | 1994-03-29 | — | — | US | claimed |
| EP-0552380-A1 | CELL CULTURE SUPPORT, PRODUCTION THEREOF, AND PRODUCTION OF CELL CLUSTER USING SAME | Kao Corporation (JP) | 1993-07-28 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060171930-A1 | Postpartum cells derived from umbilical cord tissue, and methods of making, culturing, and using the same | PGF, PLAUR, CD68 | LMNA 2603/4885SMN1; SMN2 1658/4885USP2 1579/4885 |
| US-20230055665-A1 | DELIVERY CARRIER INTO CELL | CTSA, ATG4A, ATG7 | LMNA 1046/4885SMN1; SMN2 3062/4885USP2 199/4885 |
| US-20260040695-A1 | A METHOD TO GENERATE CONDUCTIVE POLYMER | PIEZO1, LCP1, MTCL3 | LMNA 1730/4885SMN1; SMN2 531/4885USP2 3685/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.